Patients with History of Myocardial Infarction and Acute Cerebrovascular Accidentin Clinical Practice: Demographic, Clinical Characteristics, Drug Treatment and Outcomes (Data of Outpatient and Hospital Registry REGION)

Aim. To assess the demographic and clinical characteristics, drug treatment and outcomes in patients with a history of acute cerebrovascular accident (ACVA) and with concomitant history of myocardial infarction (MI) in clinical practice based on outpatient and hospital parts of REGION registry.

Material and methods. The total 1886 patients with a history of ACVA (aged of 70.6±12.5 years, 41.9% men) were enrolled into the outpatient registry REGION (Ryazan) and the hospital registry REGION (Moscow). 356 patients had ACVA and a history of MI (group “ACVA+MI” and 1530 patients had ACVA without history of MI (group “ACVA without MI”). The incidence of cardiovascular diseases (CVD), non-CVD comorbidities, drug therapy and outcomes were analyzed.

Results. In the group ACVA+MI compared with group ACVA without MI the significantly higher proportions of patients with the following conditions (diagnosis) were revealed: arterial hypertension (AH) – 99.1% and 94.2%; coronary heart disease (CHD) – 100% and 57%; chronic heart failure (CHF) – 61.5% and 41.8%; atrial fibrillation (AF) – 42.7% and 23.8%; repeated ACVA – 32.9% and 18.9%, respectively, p<0.0001 for all. In ACVA+MI and ACVA without MI groups the respective proportions of patients were smokers – 16.2% and 23.7% (p=0.10), had a family history of premature CVD – 3.2% and 1.2% (p=0.01), and had a hypercholesterolemia – 47% and 59.7% (p<0.001). The incidence of drug administration with proved positive prognostic effect was insufficient in both groups, but higher in the ACVA+MI group compared with ACVA without MI group (on average 47.1% and 40%, respectively), including: anticoagulants in AF – 19.1% and 21.4% (p=0.55); antiplatelets in CHD without AF – 69.4% and 42% (p<0.001); statins in CHD – 26.4% and 17.2% (p<0.001); beta-blockers in CHF – 39% and 23.8% (p=0.002), respectively. During 4- year follow-up in the group ACVA+MI compared with group ACVA without MI there were significantly higher all-cause mortality – 44.9% and 26.8% (p<0.001), nonfatal recurrent ACVA – 13.7% and 5.6% (p=0.0001), and nonfatal MI – 6.9% and 1.0% (p<0.0001), respectively.

Conclusion. The proportion of patients with a history of MI was 18.9% among the patients with a history of ACVA. In patients of ACVA+MI group, compared with patients of ACVA without MI group a higher incidence of the following characteristics was revealed: a presence of AH, CHD, CHF, AF, repeated ACVA and a family history of premature CVD. The incidence of taking drug with proved positive effect on prognosis in patients of the compared groups was insufficient, especially of statins and anticoagulants in AF. During the follow-up period ACVA+MI group was characterized by a higher all-cause mortality and higher incidence of nonfatal ACVA and MI. In these patients the improvement of the quality of pharmacotherapy and of the secondary prevention effectiveness are the measures of especial importance. 

1. Benjamin E.J., Muntner P., Alonso A. et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. DOI:10.1161/CIR.0000000000000659.

2. Skvortsova V.I., Shetova I.M., Kakorina E.P., et al. Reduction in stroke death rates through a package of measures to improve medical care for patients with vascular diseases in the Russian Federation. The Russian Journal of Preventive Medicine. 2018;21(1):4-10 (In Russ.) DOI:10.17116/profmed20182114-10.

3. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2016: 37; 2315-2381. DOI:10.1093/eurheartj/ehw106.

4. CARDIOVASCULAR PREVENTION 2017. NATIONAL GUIDELINES. Russ J Cardiol 2018; 23 (6): 7-122. http://dx.doi.org/10.15829/1560-4071- 2018-6-7-122

5. Boytsov S.A., Martsevich S.Y., Kutishenko N.P., et al. REGISTERS IN CARDIOLOGY: THEIR PRINCIPLES, RULES, AND REAL-WORD POTENTIAL. Cardiovascular Therapy and Prevention 2013;12(1):4-9. (In Russ.) DOI:10.15829/1728-8800-2013-1-4-9

6. Martsevich S.Y., Kutishenko N.P., Suvorov A.Y., et al. Characteristics of patients with cerebral stroke or transient ischemic attack, included in the register of LIS-2 (Lyubertsy study mortality in patients after stroke). Rational Pharmacotherapy in Cardiology 2015; 11(1): 18-24. ( In Russian). DOI:10.20996/1819-6446-2015-11-1-18-24

7. Kotova E.Y., Mashin V.V. Epidemiology and major risk factors for the development of stroke in Ulyanovsk (according to the register of stroke). Ulyanovsk medico-biological journal 2011;2:100- 107.

8. Chugunova S.A., Nikolaeva T.Y., Kuzmina Z.M., et al. Stroke epidemiology in Yakutsk based on the population-based register in 2015. Far East Medical Journal. 2017;3:80-5 (In Russ.).

9. Loukianov M.M., Yakushin S.S., Martsevich S.Y., et al. Cardiovascular Diseases and Drug Treatment in Patients with the History of Cerebral Stroke: Data of the Outpatient Registry REGION. Rational Pharmacotherapy in Cardiology. 2018;14(6):879-86 (In Russ.). DOI:10. 20996/1819-6446-2018-14-6-879-886.

10. Martsevich S.Y., Kutishenko N.P., Lukyanov M.M., et al. The study Hospital register of patients with acute cerebrovascular accident (REGION): characteristics of patient and outcomes of hospital treatment. Cardiovascular Therapy and Prevention. 2018;17(6):32-8 (In Russ.) DOI:10.15829/1728-8800-2018-6-32-38.

11. Ntaios G., Georgiopoulos G., Koroboki E., et al. Validation of the PREMISE score in the Athens Stroke Registry. Journal of Stroke and Cerebrovascular Diseases. 2019;28(7):1806-9. DOI:10.1016/j.jstrokecerebrovasdis.2019.04.023.

12. Venketasubramanian N., Yoon B.W., Pandianet J., et al. Stroke in South, East, and South-East Asia: Review. Journal of Stroke. 2017;19(3):286-94. DOI:10.5853/jos.2017.00234.

13. Takashima N., Arima H., Kita Y. Two-Year Survival After First-Ever Stroke in a General Population of 1.4 Million Japanese - Shiga Stroke Registry. Circ J. 2018;82(10):2549-2556. DOI:10.1253/circj.CJ-18-0346.

14. Magomaev M.F. Prognosis of morbidity of stroke in the Dagestan Republic. Korsakov S.S. Neuroscience and Behavioral Physiology Journal. 2015;115:3(2):59-63 (In Russ.) DOI:10.17116/jnevro20151153259-63.

15. Jang M.U., Kang J., Kim B.J., et al. In-Hospital and Post-Discharge Recovery after Acute Ischemic Stroke: a Nationwide Multicenter Stroke Registry-base Study. J Korean Med Sci. 2019;34(36):e240. DOI:10.3346/jkms.2019.34.e240.

16. Echouffo-Tcheugui J.B., Xu H., Matsouaka R.A., et al. Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. Eur Heart J. 2018:0;1-11 DOI:10.1093/eurheartj/ehy036.

17. Al Rukn S., Mazya M.V., Hentati F., et al. Stroke in the Middle-East and North Africa: A 2-year prospective observational study of stroke characteristics in the region - Results from the Safe Implementation of Treatments in Stroke (SITS) - Middle-East and North African (MENA). International Journal of Stroke. 2019:0(0);1-8. DOI:10.1177/1747493019830331.

18. Lindmark A., Glader E.L., Asplund K. Socioeconomic disparities in stroke case fatality - Observations from Riks-Stroke, the Swedish stroke register. International Journal of Stroke. 2014:9;429-36. DOI:10.1111/ijs.12133.